Clinical trials: Autologous Hematopoietic Stem Cell Transplant
Multiple Myeloma, Non-Hodgkins Lymphoma
Study of the Best Timing for Plerixafor in Autologous Hematopoietic Stem Cell Collection
The purpose of this study is to determine whether it is safe and effective to collect peripheral blood hematopoietic stem cells 16 hours rather than the usual 11 hours after administration of plerixafor.
- Trial name
- NCT01042717
- Testing
- Plerixafor
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Shi, Patricia, M.D.
Cancer, Multiple Myeloma
Combination High Dose Melphalan and Autologous Peripheral Blood Stem Cell (PBSC) Transplant With Bortezomib for Multiple Myeloma: A Dose and Schedule Finding Study
The goal of this study is to evaluate the safety of melphalan and autologous PBSCT (peripheral blood stem cell transplantation - stem cells that come from your own body) in combination with bortezomib, a new FDA approved drug…
- Trial name
- NCT00793650
- Testing
- Bortezomib, Melphalan, Autologous PBSC Transplant
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Emory University
Kidney Failure, Chronic, Kidney Transplantation
Immunological Reset to Enable Access to Hla-compatible Kidney Transplantation in Highly Sensitized Patients (RESET)
The purpose of this clinical trial is to evaluate whether a temporary reprogramming of the immune system can help highly sensitized (hyperimmunized) patients with end-stage kidney disease safely receive a compatible kidney…
- Conditions
- Kidney Failure, Chronic, Kidney Transplantation, Alloimmunization, HLA Sensitization
- Trial name
- HIPER-RESET (NCT07607197)
- Testing
- Autologous Hematopoietic Stem Cell Transplantation
- Where
- Spain
- Volunteers
- 10 people
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
Multiple Myeloma
Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple Myeloma
The goal of this clinical trial is to compare a maintenance therapy consisting of iberdomide and isatuximab with an iberdomide-only regimen.
- Trial name
- NCT06216158
- Testing
- Iberdomide, Isatuximab, Dexamethasone
- Where
- 69 sites in Austria, Germany
- Volunteers
- 411 people
- Sponsor
- University of Heidelberg Medical Center
Cardiomyopathy
Characteristics of Patients With Amyloidosis & Heart Failure Being Evaluated for a Heart Transplant
The purpose of this study is to describe the characteristics of patients with amyloidosis and severe heart failure being evaluated for cardiac and stem cell transplantation.
- Trial name
- NCT00456040
- Volunteers
- 25 people
- Sponsor
- Massachusetts General Hospital
Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Busulfan and Etoposide Followed by Peripheral Blood Stem Cell Transplant and Low-Dose Aldesleukin in Treating Patients With Acute Myeloid Leukemia
This phase II trial studies the side effects and how well giving busulfan and etoposide followed by peripheral blood stem cell transplant (PBSCT) and low-dose aldesleukin works in treating patients with acute myeloid leukemia…
- Conditions
- Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
- Trial name
- NCT00003875
- Testing
- busulfan, etoposide, aldesleukin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Fred Hutchinson Cancer Center
Multiple Myeloma, Amyloidosis
Study of Captisol Enabled Melphalan and Pharmacokinetics for Patients With Multiple Myeloma or Light Chain Amyloidosis That Are Receiving an Autologous Transplant.
Captisol Enabled Melphalan, is a new formulation of the standard of care melphalan chemotherapy that in packaged in an inactive substance that is believed to help the chemotherapy be more stable (meaning that it doesn't lose its…
- Trial name
- NCT02909036
- Testing
- Melphalan, Pegfilgrastim, Autologous Hematopoietic Progenitor Cell Transplant
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Multiple Myeloma
A Plant-Based Whole-Foods Meal Delivery Service for Patients With Multiple Myeloma Undergoing Autologous Hematopoietic Cell Transplant
This clinical trial evaluates the impact of a plant-based whole-foods delivery service on the microbiome in patients with multiple myeloma undergoing an autologous hematopoietic cell transplant.
- Trial name
- NCT06559709
- Testing
- Biospecimen Collection, Dietary Intervention, Medical Chart Review
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Fred Hutchinson Cancer Center
Multiple Myeloma, Lymphoma
Busulfan Plus Melphalan Conditioning Regimen for Lymphoid Malignancies or Multiple Myeloma
Primary Objectives: 1. To determine the efficacy of administering multiple doses of intravenous (i.v.) busulfan at a dose of 130 mg/m2, to yield a systemic plasma drug exposure represented by a daily area under the plasma…
- Trial name
- NCT00427765
- Testing
- Busulfan, Melphalan
- Where
- United States
- Volunteers
- 168 people
- Sponsor
- M.D. Anderson Cancer Center
Neuroblastoma
Autologous Transplant Followed by Allogeneic Transplant for High Risk Neuroblastoma
Neuroblastoma is a malignant tumor of the sympathetic nervous system. It is the second most common malignant tumor of childhood.
- Trial name
- NCT00670410
- Testing
- Related donor transplant, Cord blood transplant, Busulfan
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Columbia University
Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma
Autologous or Donor Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma (BMT CTN 0202)
This study is designed as a Phase II/III, multi-center trial, comparing two transplant strategies to determine whether non-myeloablative allogeneic Hematopoietic Stem Cell Transplantation (HSCT) will improve long-term…
- Conditions
- Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Follicular Lymphoma
- Trial name
- NCT00096460
- Testing
- Cyclophosphamide and Rituximab, Filgrastim, Chemotherapy or Radiation therapy
- Where
- 30 sites in United States
- Volunteers
- 30 people
- Sponsor
- Medical College of Wisconsin
Ovarian Cancer, Peritoneal Cavity Cancer
Topotecan, High-Dose Cyclophosphamide, Carboplatin, and an Autologous Peripheral Blood Cell Transplant in Treating Patients With Recurrent Ovarian Cancer or Primary Peritoneal Cancer
RATIONALE: Giving colony-stimulating factors, such as G-CSF help stem cells move from the patient's bone marrow to the blood so they can be collected and stored.
- Trial name
- NCT00652691
- Testing
- filgrastim, carboplatin, cyclophosphamide
- Volunteers
- 48 people
- Sponsor
- Mayo Clinic
REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS
Autologous Stem Cell Transplantation: International Lupus Trial
The purpose of this study is to evaluate remission induction therapy for refractory Lupus Erythematosus with autologous hematopoietic stem cell transplantation (AHSCT) versus Rituximab (anti CD20) followed by maintenance therapy…
- Trial name
- ASTIL (NCT05063513)
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, Rituximab
- Where
- France
- Sponsor
- European Society for Blood and Marrow Transplantation
Bone Marrow Transplant - Autologous or Allogeneic
Donor Human Milk in Young Children Receiving Bone Marrow Transplantation
The investigators hypothesize that children receiving human milk will maintain a greater diversity of helpful bacteria in their gut and have lower levels of inflammatory proteins in the blood compared with children not receiving…
- Trial name
- NCT02470104
- Testing
- Breastmilk
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Sickle Cell Disease
A Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantation in Patients With Severe Sickle Cell Disease
This is an open label, multicenter, Phase 1/2 study in approximately eight adults with severe Sickle Cell Disease (SCD). The study will evaluate the safety, tolerability, and efficacy of autologous hematopoietic stem cell…
- Trial name
- NCT03653247
- Testing
- Plerixafor, Busulfan, BIVV003
- Where
- 5 sites in United States
- Volunteers
- 7 people
- Sponsor
- Sangamo Therapeutics
Diffuse Large Cell Lymphoma
ACVBP Plus Rituximab in Patients Aged From 18 to 59 Years With High-risk Diffuse Large B-cell Lymphoma
This study is a multicentric trial evaluating the efficacy of R-ACVBP in patients aged 18 to 59 years with high risk diffuse large B-cell lymphoma
- Trial name
- NCT00144807
- Testing
- rituximab, doxorubicin, cyclophosphamide
- Where
- 13 sites in Belgium, France and 1 more
- Volunteers
- 128 people
- Sponsor
- Lymphoma Study Association
Multiple Myeloma
Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma
Phase I: The primary purpose of this study phase is to determine the best dose also referred to as the maximum tolerated dose (MTD) of Selinexor when used in combination with high-dose melphalan as a conditioning regimen for…
- Trial name
- NCT02780609
- Testing
- Selinexor, Melphalan, Dexamethasone
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Multiple Myeloma, Newly Diagnosed
CAR-T vs. Auto-SCT: Which Works Better for New Myeloma Patients?
This is a prospective study comparing anti-BCMA CAR-T to autologous hematopoietic stem cell transplantation alone in the treatment of newly diagnosed multiple myeloma patients.
- Trial name
- ASCTvsCAR-T (NCT07070934)
- Testing
- CAR-T, ASCT
- Volunteers
- 60 people
- Sponsor
- Xuzhou Medical University
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Ixazomib Citrate, Pomalidomide, Dexamethasone, Stem Cell Transplant in Treating Relapsed or Refractory Multiple Myeloma
This phase II trial studies how well ixazomib citrate, pomalidomide, dexamethasone, and stem cell transplantation works in treating patients with multiple myeloma that has come back or does not respond to treatment.
- Trial name
- NCT03202628
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, Dexamethasone, Ixazomib Citrate
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Mayo Clinic
Autoimmune Diseases
Cancer as a complicATion in reCipients of Autologous Hematopoietic Stem Cell Transplantation for Autoimmune Disease iNdiCation trEated in FRance and Canada?
Autologous Hematopoietic Stem Cell Transplantation (AHSCT) is a treatment option for several types of Autoimmune Disease (AD) in patients who remain active despite disease modifying therapies.
- Trial name
- CATCH CANCER (NCT06507800)
- Testing
- Observational cohort
- Volunteers
- 500 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris